Cuprina and Aiodine Laboratory Establish Joint Venture Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Joint Venture Agreement: Cuprina has partnered with Singapore's Aiodine Laboratory to develop and market a novel iodine-based disinfectant solution for treating chronic and acute wounds.
Initial Applications: The focus will be on antiseptic wound care formulations, disinfectants, and daily home-use antiseptics, with potential expansions into personal care, oral hygiene, and veterinary applications.
Clinical Studies Timeline: The companies plan to begin clinical studies necessary for regulatory approvals in 2026.
Market Potential: The collaboration aims to explore various applications of the iodine-based solution beyond wound care, indicating a broad market potential.
Analyst Views on CUPR
About CUPR
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
